Yuying Huang

Yuying Huang

Auto-generated profile, based on publicly available information

Yuying Huang

Key Laboratory of Multi-Cell Systems, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YHYuying Huang
Yuying Huang
LZLin Zhu
Lin Zhu
SCShipeng Cheng
Shipeng Cheng
RDRanran Dai
Ranran Dai
CHChunrong Huang
Chunrong Huang
BSBing Sun
Bing Sun
The immunomodulatory effects of ultraviolet B (UVB) radiation in human diseases have been described. Whether type 2 lung inflammation is directly affected by solar ultraviolet (UV) radiation is not fully understood. Here, we show a possible negative correlation between solar UVB radiation and asthmatic inflammation in humans and mice. UVB exposure to the eyes induces hypothalamus-pituitary activation and α-melanocyte-stimulating hormone (α-MSH) accumulation in the serum to suppress allergic airway inflammation by targeting group 2 innate lymphoid cells (ILC2) through the MC5R receptor in mice. The α-MSH/MC5R interaction limits ILC2 function through attenuation of JAK/STAT and NF-κB signaling. Consistently, we observe that the plasma α-MSH concentration is negatively correlated with the number and function of ILC2s in the peripheral blood mononuclear cells (PBMC) of patients with asthma. We provide insights into how solar UVB radiation-driven neuroendocrine α-MSH restricts ILC2-mediated lung inflammation and offer a possible strategy for controlling allergic diseases.

2 April 2026 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
LZLin Zhu
Lin Zhu
YHYuying Huang
Yuying Huang
BPBo Peng
Bo Peng
SZShufeng Zhong
Shufeng Zhong
XZXiaoyu Zhang
Xiaoyu Zhang
BSBing Sun
Bing Sun

16 October 2026 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
BPBo Peng
Bo Peng
SSSiying Sun
Siying Sun
LZLin Zhu
Lin Zhu
SZShufen Zhong
Shufen Zhong
XCXixi Chen
Xixi Chen
WTWei Tang
Wei Tang
Group 2 innate lymphoid cells (ILC2s) play a critical role in initiating the type 2 immune response, particularly in allergic airway diseases. Although the effects of glutamate on the immune system have been reported previously, its role in modulating the function of ILC2s and lung inflammation remains unclear. In this study, we report that the glutamate levels increased in lung tissue following exposure to allergens. Consequently, glutamate was found to restrain ILC2 responses during lung inflammation in mice. Using Rag1 −/− mice, we demonstrated that the inhibitory effect of glutamate on type 2 inflammation was independent of T and B cells. Further ILC2 adoptive transfer experiments in Rag −/− Il2rg −/− mice confirmed that glutamate likely exerted its effects by directly targeting ILC2s. In vitro experiments revealed that glutamate suppressed ILC2 function through ionic kainate receptor signaling. Genetic deletion of the kainate receptor subunit GluK2 enhanced ILC2 responses and exacerbated type 2 lung inflammation. Mechanistically, transcriptome and metabolic analyses revealed that glutamate reduced oxidative metabolism in ILC2s, thereby limiting their activation. Consistently, in vivo administration of BPAM344—a positive allosteric modulator that potentiates GluK2 signaling—effectively suppressed allergen-induced type 2 inflammation. Notably, ILC2-specific GluK2 deletion markedly attenuated the anti-inflammatory effects of BPAM344, indicating that its protective effects depend on ILC2-intrinsic GluK2 signaling. These findings demonstrate a novel role for glutamate in restraining ILC2 function, as it plays a protective role in alleviating airway inflammation. We propose that GluK2 activation may offer a promising therapeutic strategy for treating ILC2-driven allergic asthma.

16 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
SZShufen Zhong
Shufen Zhong
LSLiming Sun
Liming Sun
JQJinxin Qiu
Jinxin Qiu
BPBo Peng
Bo Peng
SSSiying Sun
Siying Sun
BSBing Sun
Bing Sun
Interleukin-33 (IL-33) from lung epithelial cells serves as a crucial alarmin to activate the lung-resident group 2 innate lymphoid cells (ILC2s) and then to initiate type 2 inflammation. However, whether IL-33 has an intrinsic role in the ILC2-driven lung inflammation remains unclear. In this study, we characterize the proteomic features of mouse lung ILC2s during activation and observe an increased expression of intrinsic IL-33 in activated ILC2s. The expression of intrinsic IL-33 in lung ILC2s can be induced by the co-stimulation of cysteinyl leukotrienes (CysLTs) and exogenous IL-33. Deletion of ILC2-intrinsic IL-33 attenuates lung inflammation by restraining ILC2 proliferation and cytokine production. Mechanistically, ILC2-intrinsic IL-33 promotes transcriptional activation of both inflammatory and proliferative signaling cascades. Additionally, ILC2-intrinsic IL-33 localizes in the nucleus and promotes the expression of Fosl2 and Nfatc1 through promoting their chromatin accessibility, leading to increased ILC2 proliferation and type 2 cytokine production. Further, we confirm that intrinsic IL-33 can be induced by co-stimulation of CysLTs and exogenous IL-33 in human ILC2s (hILC2s), which is positively related to enhanced hILC2 responses. Collectively, our findings implicate IL-33 as a nuclear factor and intrinsic amplifier of lung-resident ILC2s, operating in a positive feedback loop downstream of exogenous IL-33 and CysLTs co-stimulation to promote allergic lung inflammation.